FDA Affirms Efficacy Of Savient's Gout Treatment


An FDA memo reaffirmed the efficacy of a gout drug treatment developed by Savient Pharmaceutical Inc. (Nasdaq: SVNT), but identified other risks to patients. The stock price leaped $3.33 to close at $9.26.

About this Entry

This page contains a single entry by published on June 12, 2009 2:37 PM.

Symantec Warns Of Margin Pressure was the previous entry in this blog.

Saks Upgraded is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12